losartan has been researched along with Diabetes Mellitus in 40 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 9.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 9.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 9.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 9.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 9.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 9.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 9.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 7.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 7.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 6.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 5.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "The FANTASTIC is a clinical study to provide: (1) the reno-protective effect of fimasartan; and (2) the target BP to reduce adverse outcomes in hypertensive diabetic CKD with overt proteinuria." | 5.24 | FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial. ( Chin, HJ; Kim, JY; Kim, YJ; Park, S; Ryu, DR; Son, JW; Yoo, TH, 2017) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 5.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| "The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed." | 5.14 | A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. ( Bastien, N; Hamet, P; Longo, N; Racine, N; Sampalis, JS, 2010) |
| " STAR-LET was a 6-month extension of the Study of Trandolapril/Verapamil SR and Insulin Resistance (STAR), which assessed the effects of a fixed-dose renin-angiotensin system inhibitor (RASI)/hydrochlorothiazide (HCTZ) combination on changes in 2-hour oral glucose tolerance test (OGTT) results." | 5.13 | Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. ( Bacher, P; Bakris, G; Champion, A; Molitch, M; Sarafidis, P; Sowers, JR; Zhou, Q, 2008) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 5.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "A total of 9193 hypertensive patients (1195 with diabetes) in the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study were treated with losartan- or atenolol-based regimens and followed up with serial ECG and blood pressure determinations at baseline and 6 months and then yearly until death or study end." | 5.12 | Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Gerdts, E; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Lindholm, LH; Okin, PM; Snapinn, SM, 2006) |
| "In the LIFE study, with a double-masked, randomized, parallel-group design, 9193 patients (46% men) with hypertension (mean age 67 years, average pressure 174/98 mmHg after placebo run-in) and electrocardiogram-documented left ventricular hypertrophy were randomly assigned to once-daily losartan- or atenolol-based antihypertensive treatment and followed for at least 4 years (mean 4." | 5.10 | Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. ( Aurup, P; Beevers, G; Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Snapinn, S; Wachtell, K; Wedel, H, 2002) |
| "Losartan induced a drastic decrease in proteinuria accompanied by a reduction in urinary excretion of TGF-beta in patients with non-diabetic proteinuric renal diseases." | 5.10 | Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. ( Aguirre, R; Andrade, CF; Ara, JM; Arias, M; Bernis, C; Campistol, JM; Galceran, JM; Luño, J; Marín, R; Mora, J; Poveda, R; Praga, M; Prat, MV; Rivera, F, 2003) |
| " We investigated the effect of switching from an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) to a combination of losartan and hydrochlorothiazide on left ventricular (LV) relaxation in patients with hypertension and diastolic dysfunction." | 3.78 | Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension. ( Fukuda, S; Ishii, K; Ito, H; Iwakura, K; Shimada, K; Takami, T; Watanabe, H; Yoshikawa, J, 2012) |
| "To assess the therapeutic effect of losartan on type 2 diabetes mellitus (DM2) with gas chromatography (GC)-based metabonomics." | 3.74 | [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics]. ( Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007) |
| "Treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy with losartan-based therapy is associated with lower incidence of diabetes mellitus and greater regression of hypertrophy than atenolol-based therapy." | 3.74 | In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) ( Dahlöf, B; Devereux, RB; Harris, KE; Jern, S; Kjeldsen, SE; Lindholm, LH; Okin, PM, 2007) |
| "In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
| " MASSIVE PROTEINURIA: An angiotensin II inhibitor, losartan, has been found to be effective against massive proteinuria (> 3." | 3.71 | [Complications in kidney transplantation]. ( Ouali, N, 2001) |
| " Thus, we aim to evaluate whether losartan potassium combined with KLX is more effective than losartan potassium in DKD treatment and to provide validated evidence for the application of KLX in the treatment of DKD." | 2.94 | Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial. ( Bai, L; Li, F; Li, J; Qu, L; Wang, Q; Wei, F; Wei, J; Wu, R; Yan, W, 2020) |
| "Losartan was very effective in reducing cardiovascular morbidity and mortality as compared to atenolol." | 2.71 | [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]. ( Dahlöf, B; Ibsen, H; Kjeldsen, S; Lindholm, LH; Pedersen, OL, 2003) |
| " Further research is necessary to determine which AT1RBs and which dosing regimens are optimal." | 2.41 | Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. ( Mancini, GB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (72.50) | 29.6817 |
| 2010's | 8 (20.00) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Yoo, TH | 2 |
| Hong, SJ | 1 |
| Kim, S | 1 |
| Shin, S | 1 |
| Kim, DK | 1 |
| Lee, JP | 1 |
| Han, SY | 1 |
| Lee, S | 1 |
| Won, JC | 1 |
| Kang, YS | 1 |
| Park, J | 1 |
| Han, BG | 1 |
| Na, KR | 1 |
| Hur, KY | 1 |
| Kim, YJ | 2 |
| Park, S | 2 |
| Cooper, TE | 1 |
| Teng, C | 1 |
| Tunnicliffe, DJ | 1 |
| Cashmore, BA | 1 |
| Strippoli, GF | 1 |
| Wu, R | 1 |
| Wei, F | 1 |
| Qu, L | 1 |
| Bai, L | 1 |
| Li, J | 1 |
| Li, F | 1 |
| Yan, W | 1 |
| Wang, Q | 1 |
| Wei, J | 1 |
| Kim, JY | 1 |
| Son, JW | 1 |
| Ryu, DR | 1 |
| Chin, HJ | 1 |
| Alvarez, M | 1 |
| Ardiles, L | 1 |
| Chen, C | 1 |
| Zhang, Z | 1 |
| Li, Z | 1 |
| Zhang, F | 1 |
| Peng, M | 1 |
| Chen, Y | 1 |
| Wang, Y | 1 |
| Yuan, KL | 1 |
| Shi, XZ | 1 |
| Lu, X | 1 |
| Gao, P | 1 |
| Xu, GW | 1 |
| Racine, N | 1 |
| Hamet, P | 1 |
| Sampalis, JS | 1 |
| Longo, N | 1 |
| Bastien, N | 1 |
| Yamamoto, K | 1 |
| Ozaki, H | 1 |
| Takayasu, K | 1 |
| Akehi, N | 1 |
| Fukui, S | 1 |
| Sakai, A | 1 |
| Kodama, M | 1 |
| Shimonagata, T | 1 |
| Kobayashi, K | 1 |
| Ota, M | 1 |
| Horiguchi, Y | 1 |
| Ebisuno, S | 1 |
| Katsube, Y | 1 |
| Yamazaki, T | 1 |
| Ohtsu, H | 1 |
| Hori, M | 1 |
| Ram, CV | 1 |
| Ramaswamy, K | 1 |
| Qian, C | 1 |
| Biskupiak, J | 1 |
| Ryan, A | 1 |
| Quah, R | 1 |
| Russo, PA | 1 |
| Takami, T | 1 |
| Ito, H | 1 |
| Ishii, K | 1 |
| Shimada, K | 1 |
| Iwakura, K | 1 |
| Watanabe, H | 1 |
| Fukuda, S | 1 |
| Yoshikawa, J | 1 |
| Suzuki, H | 1 |
| Shimada, Y | 1 |
| Fujiwara, K | 1 |
| Lindholm, LH | 6 |
| Ibsen, H | 5 |
| Borch-Johnsen, K | 3 |
| Olsen, MH | 4 |
| Wachtell, K | 4 |
| Dahlöf, B | 7 |
| Devereux, RB | 4 |
| Beevers, G | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 2 |
| Julius, S | 2 |
| Kjeldsen, SE | 4 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 1 |
| Nieminen, MS | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Wedel, H | 1 |
| Aurup, P | 1 |
| Edelman, JM | 3 |
| Snapinn, S | 2 |
| Malik, RA | 1 |
| Mancini, GB | 1 |
| Pedersen, OL | 1 |
| Kjeldsen, S | 1 |
| Ye, G | 1 |
| Metreveli, NS | 1 |
| Ren, J | 1 |
| Epstein, PN | 1 |
| Praga, M | 1 |
| Andrade, CF | 1 |
| Luño, J | 1 |
| Arias, M | 1 |
| Poveda, R | 1 |
| Mora, J | 1 |
| Prat, MV | 1 |
| Rivera, F | 1 |
| Galceran, JM | 1 |
| Ara, JM | 1 |
| Aguirre, R | 1 |
| Bernis, C | 1 |
| Marín, R | 1 |
| Campistol, JM | 1 |
| Aronow, WS | 1 |
| Sidorenko, BA | 1 |
| Ugriumova, MO | 1 |
| Wargo, KA | 1 |
| Chong, K | 1 |
| Chan, EC | 1 |
| Ong, HT | 1 |
| Chong, AY | 1 |
| Lip, GY | 1 |
| Nomura, S | 1 |
| Shouzu, A | 1 |
| Omoto, S | 1 |
| Nishikawa, M | 1 |
| Iwasaka, T | 1 |
| Kohno, M | 1 |
| Yoshida, D | 1 |
| Higashiura, K | 1 |
| Shimamoto, K | 1 |
| Franklin, SS | 1 |
| Papademetriou, V | 1 |
| Mogensen, CE | 1 |
| Snapinn, SM | 2 |
| Wan, Y | 1 |
| Lyle, PA | 1 |
| Okin, PM | 2 |
| Gerdts, E | 1 |
| Harris, KE | 2 |
| Jern, S | 2 |
| Chrysant, SG | 1 |
| Chrysant, GS | 1 |
| Baumgart, P | 1 |
| Schillaci, G | 1 |
| Pirro, M | 1 |
| Mannarino, E | 1 |
| de Zeeuw, D | 1 |
| Raz, I | 1 |
| Bakris, G | 1 |
| Molitch, M | 1 |
| Zhou, Q | 1 |
| Sarafidis, P | 1 |
| Champion, A | 1 |
| Bacher, P | 1 |
| Sowers, JR | 1 |
| Carlson, SH | 1 |
| Shelton, J | 1 |
| White, CR | 1 |
| Wyss, JM | 1 |
| Paul, B | 1 |
| Sapra, B | 1 |
| Maheshwari, S | 1 |
| Goyal, RK | 1 |
| Ouali, N | 1 |
| Studney, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02620306] | Phase 3 | 351 participants (Actual) | Interventional | 2016-02-11 | Completed | ||
| 52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome[NCT00546052] | Phase 3 | 1,738 participants (Actual) | Interventional | 2005-09-01 | Completed | ||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors [NCT00140985] | Phase 4 | 97 participants (Actual) | Interventional | 2000-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Absolute Change in C Reactive Protein Between Baseline and 52 week assessments: C Reactive Protein 52 weeks - C Reactive Protein Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mg/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -0.36 |
Absolute Change in Uric Acid Between Baseline and 52 week assessments: Uric Acid 52 weeks - Uric Acid Baseline. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -19.17 |
Absolute change in Body Mass Index Baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Kg/m2 (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -7.3 |
Absolute change in Diastolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -9.84 |
Absolute Change in Fasting Blood Glucose Measurements between Baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mmol/L (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.02 |
Absolute Change in Hemoglobin A1c between 52 week measurement and baseline value. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.04 |
Absolute change in Systolic Blood Pressure between baseline and 52 week assessments. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | mm Hg (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -16.95 |
Absolute change in Waist Circumference between baseline and 52 week assessments (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | cm (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.28 |
Percent Change in HDL-C Between Baseline and 52 week assessments: 100% x [(HDL-C 52 Weeks - HDL-C 52 Baseline) / (HDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 0.21 |
Percent Change in LDL-C Between Baseline and 52 week assessments: 100% x [(LDL-C 52 Weeks - LDL-C Baseline) / (LDL-C Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -1.49 |
Percent Change in Total Cholesterol Between Baseline and 52 week assessments: 100% x [(Total Cholesterol 52 weeks - Total Cholesterol Baseline) / (Total Cholesterol Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Mean) |
|---|---|
| Losartan +/- Hydrochlorothiazide | -2.98 |
Percent Change in Triglycerides Between Baseline and 52 week assessments: 100% x [(Triglycerides 52 Weeks - Triglycerides Baseline) / (Triglycerides Baseline)]. (NCT00546052)
Timeframe: 52 Weeks - Baseline
| Intervention | Percent Change (Median) |
|---|---|
| Losartan +/- Hydrochlorothiazide | 1.09 |
Target Blood Pressure defined as Systolic Blood Pressure/Diastolic Blood Pressure ≤ 140/90 mm Hg at 52 weeks (NCT00546052)
Timeframe: 52 Weeks
| Intervention | Participants (Number) | |
|---|---|---|
| Achieved Target Blood Pressure | Did NOT achieve target Blood Pressure | |
| Overall Intend to Treat | 1200 | 514 |
| Overall Per Protocol | 1200 | 311 |
| Overall Total | 1200 | 538 |
8 reviews available for losartan and Diabetes Mellitus
| Article | Year |
|---|---|
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus | 2023 |
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary A | 2002 |
[New perspectives of the use of angiotensin II receptor blocker].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diabetes Mellit | 2003 |
[Hypertension in patients with cardiac hypertrophy].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2004 |
[Treatment of hypertensive patients with impaired glucose tolerance (IGT)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
The pleiotropic effects of angiotensin receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2006 |
Role of losartan therapy in the management of diabetic hypertension.
Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypertension; Losartan; Randomized Controlled Tri | 2000 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
12 trials available for losartan and Diabetes Mellitus
| Article | Year |
|---|---|
The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2022 |
Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
Topics: Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Drugs, Chinese Herbal; Glomerular Fi | 2020 |
FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials, Phase III | 2017 |
A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Glu | 2010 |
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte | 2011 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Double-Blind Method; | 2002 |
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diabe | 2003 |
Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.
Topics: Adult; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blocke | 2003 |
Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus.
Topics: Aged; Angiotensin Receptor Antagonists; Biomarkers; Blood Pressure; Chemokines; Diabetes Complicatio | 2004 |
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2006 |
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Complications; Diabetes Mellitu | 2006 |
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus; Diuretics; Female; Glucose Toleran | 2008 |
20 other studies available for losartan and Diabetes Mellitus
| Article | Year |
|---|---|
[Prescription of renin-angiotensin-aldosterone system blockers in patients with stage 3 chronic kidney disease].
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Creatinine; D | 2019 |
Losartan attenuates microvascular permeability in mechanical ventilator-induced lung injury in diabetic mice.
Topics: Angiotensinogen; Animals; Capillary Permeability; Diabetes Mellitus; Losartan; Mice; Mice, Inbred NO | 2014 |
[Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics].
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Biomarkers; Chromatography, Gas; Creatinine; Deoxyguanosin | 2007 |
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compou | 2011 |
Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; C-Reactive | 2012 |
Combination therapy with losartan/hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
No morbidity-mortality. Commentary.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atenolol; Diabe | 2002 |
Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Calcium; Diabetes Complications; Diabetes | 2003 |
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidit | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
Acute renal failure secondary to angiotensin II receptor blockade in a patient with bilateral renal artery stenosis.
Topics: Acute Kidney Injury; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Con | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
LIFE: losartan versus atenolol.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diab | 2003 |
Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Animals; At | 2005 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Left ventricular hypertrophy reversal and prevention of diabetes: two birds with one stone?
Topics: Antihypertensive Agents; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus; Electrocardiograp | 2007 |
In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE)
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Comorbidity; Diabetes Me | 2007 |
Albuminuria: a great risk marker, but an underestimated target in diabetes.
Topics: Albuminuria; Antihypertensive Agents; Biomarkers; Diabetes Mellitus; Diabetic Angiopathies; Humans; | 2008 |
Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; B | 2000 |
[Complications in kidney transplantation].
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Graft Rejection; Humans; H | 2001 |